This review highlights the evolving roles and safety profiles of oral class III antiarrhythmics in managing arrhythmias, particularly in patients with structural heart disease.
Answers are grounded in this paper and cite their sources.
Amiodarone warrants pacing preparedness in tachyarrhythmia patients; leaves open optimal class III selection in structural heart disease.
PURPOSE OF REVIEW: This review describes the latest developments in the clinical usage of class III antiarrhythmics. It also discusses some new studies providing insight into the mechanism of action of these drugs. RECENT FINDINGS: New data suggest that amiodarone is one of the most effective drugs for management of ventricular as well as supraventricular tachyarrhythmias. As over the years we have learned to deal with the toxic side effects of this drug, the risk of bradyarrhythmias requiring placement of a pacemaker is becoming more significant. Sotalol was approved for treatment of atrial fibrillation and atrial flutter (AF). It was also found to be effective in management of postoperative AF. Dofetilide has been approved for the conversion and maintenance of sinus rhythm in AF; its role in ventricular arrhythmias remains unclear. Data are emerging regarding clinical efficacy of azimilide and dronedarone. SUMMARY: Management of arrhythmias in patients with structural heart disease remains a challenge. Class III antiarrhythmics are the mainstay of treatment in this group of patients.
No takes yet. Share an insight, caveat, or question.
Mazhar H. Khan (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: